Predicting Risk and Guiding Care: Biomarkers & Genetic Testing in Prostate Cancer

GU medical oncologist Dr. Rana McKay and urologist Dr. Neal Shore explore how predictive biomarkers and genetic testing are informing risk assessment and guiding personalized treatment decisions in clinical practice.

EP: 1.Metastatic Prostate Cancer: Background and Patient Prognosis

Now Viewing

EP: 2.Predicting Risk and Guiding Care: Biomarkers & Genetic Testing in Prostate Cancer

EP: 3.Treatment Selection in Metastatic and Castration Resistant Prostate Cancer: Optimizing Outcomes and Preserving Patient Quality of Life

EP: 4.Androgen Receptor Signaling and Its Role in Driving Prostate Cancer Metastasis

EP: 5.Targeting the Androgen Receptor Pathway and Overcoming Treatment Resistance in Advanced Prostate Cancer

EP: 6.Emerging AR Targeting Agents and CDK4/6 Inhibitors in Metastatic Prostate Cancer and Potential Impact on the Treatment Landscape

EP: 7.Multidisciplinary Collaboration and Expert Insights in the Management of Advanced Prostate Cancer

Related Videos

Related Content

Advertisement

January 23rd 2025

Health-related QOL is comparable among ARPI regimens for CSPC

Hannah Clarke

At 25 weeks, FACT-P total score remained comparable between the arms.

January 14th 2025

Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

Wayne Kuang, MD Steven Maislos, MD

Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.

January 13th 2025

FDA accepts NDA for 3-month leuprolide mesylate formulation for advanced prostate cancer

Hannah Clarke

The PDUFA target action date has been set for August 29, 2025.

November 27th 2024

Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

January 7th 2025

Expanded indication sought for darolutamide in mHSPC in China

Hannah Clarke

The application is supported by data from the pivotal phase 3 ARANOTE trial.

January 1st 2025

2024 Urology Times pipeline report

Jason M. Broderick Hannah Clarke Brittany Lovely

Catch up on all the notable drug and device approvals in urology over the past year.

Related Content

Advertisement

January 23rd 2025

Health-related QOL is comparable among ARPI regimens for CSPC

Hannah Clarke

At 25 weeks, FACT-P total score remained comparable between the arms.

January 14th 2025

Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

Wayne Kuang, MD Steven Maislos, MD

Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.

January 13th 2025

FDA accepts NDA for 3-month leuprolide mesylate formulation for advanced prostate cancer

Hannah Clarke

The PDUFA target action date has been set for August 29, 2025.

November 27th 2024

Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

January 7th 2025

Expanded indication sought for darolutamide in mHSPC in China

Hannah Clarke

The application is supported by data from the pivotal phase 3 ARANOTE trial.

January 1st 2025

2024 Urology Times pipeline report

Jason M. Broderick Hannah Clarke Brittany Lovely

Catch up on all the notable drug and device approvals in urology over the past year.